Advertisement
U.S. markets open in 3 hours 35 minutes

KALA BIO, Inc. (KALA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.70+0.17 (+2.26%)
At close: 04:00PM EDT
7.54 -0.16 (-2.08%)
After hours: 04:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close7.53
Open7.62
Bid7.50 x 1000
Ask7.82 x 1200
Day's Range7.62 - 8.00
52 Week Range5.10 - 19.57
Volume26,737
Avg. Volume33,370
Market Cap20.737M
Beta (5Y Monthly)-1.86
PE Ratio (TTM)N/A
EPS (TTM)-22.38
Earnings DateMar 19, 2024 - Mar 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KALA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • KALA BIO, Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    22 hours agoArgus Research
View more
  • GlobeNewswire

    KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

    ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also

  • GlobeNewswire

    KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

    ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m.

  • GlobeNewswire

    KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,125 shares of its common stock to one new employee. The stock options were granted on January 16, 2024. The grant was